Esophagus Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ESCC MCID: ESP027 MIFTS: 58	Esophagus Squamous Cell Carcinoma (ESCC) Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma ¹¹ ¹⁴

Esophageal Squamous Cell Carcinoma ⁵⁸ ⁵ ⁴³ ¹⁶

Squamous Cell Carcinoma of the Esophagus ⁵⁸

Squamous Cell Carcinoma of Esophagus ⁷¹

Oesophagus Squamous Cell Carcinoma ¹¹

Esophageal Squamous-Cell Carcinoma ⁷⁵

Esophageal Epidermoid Carcinoma ⁵⁸

Squamous Cell Esophageal Cancer ⁵³

Scc of Oesophagus ¹¹

Scc of Esophagus ¹¹

Escc ⁵⁸

Characteristics:

Inheritance:

Squamous Cell Carcinoma of the Esophagus: Multigenic/multifactorial ⁵⁸

Prevelance:

Squamous Cell Carcinoma of the Esophagus: 1-9/100000 (Europe, Europe, Europe, Worldwide, Austria, Belgium, Croatia, Czech Republic, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Bulgaria) ⁵⁸

Age Of Onset:

Squamous Cell Carcinoma of the Esophagus: Adult,Elderly ⁵⁸

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of oesophagus

Malignant neoplasm: Cervical part of oesophagus

Malignant neoplasm: Middle third of oesophagus

Malignant neoplasm: Thoracic part of oesophagus

Malignant neoplasm: Upper third of oesophagus

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of oesophagus

Squamous cell carcinoma of oesophagus

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹¹ DOID:3748

MeSH ⁴³ D000077277

NCIt ⁴⁹ C4024

SNOMED-CT ⁶⁸ 276804009

ICD10 via Orphanet ³² C15.0 C15.1 C15.3 more

UMLS via Orphanet ⁷² C0279626

Orphanet ⁵⁸ ORPHA99977

SNOMED-CT via HPO ⁶⁹ 16932000 263731006 272039006 more

EFO ¹⁶ EFO_0005922

ICD11 ³³ 1417891145

UMLS ⁷¹ C0279626

Sources

Summaries for Esophagus Squamous Cell Carcinoma

Orphanet: ⁵⁸ Esophageal squamous cell carcinoma (ESCC) is a type of esophageal carcinoma (EC; see this term) that can affect any part of the esophagus, but is usually located in the upper or middle third.

MalaCards based summary: Esophagus Squamous Cell Carcinoma, also known as esophageal squamous cell carcinoma, is related to squamous cell carcinoma and esophageal cancer. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR296 (MicroRNA 296). The drugs Trioxsalen and Cobalt have been mentioned in the context of this disorder. Affiliated tissues include esophagus, lymph node and testis, and related phenotypes are feeding difficulties in infancy and clinodactyly of the 5th toe

Disease Ontology: ¹¹ An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

Wikipedia: ⁷⁵ Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Sources

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	31.5	MALAT1 LINC01233 HOTAIR EPIST CASC9
2	esophageal cancer	31.2	MIR296 MEG3 MALAT1 HOTAIR GAS5 CASC9
3	thyroid carcinoma	31.1	MALAT1 HOTAIR GAS5 AFAP1-AS1
4	oral squamous cell carcinoma	31.0	MIR296 MEG3 MALAT1 HOTAIR CCAT1
5	retinoblastoma	30.9	MEG3 MALAT1 HOTAIR CCAT1 BANCR
6	gastric cardia adenocarcinoma	30.9	MEG3 HOTAIR EPIST
7	gastrointestinal system cancer	30.9	MIR296 MALAT1 HOTAIR BANCR
8	small cell cancer of the lung	30.7	MALAT1 HOTTIP HOTAIR
9	pancreatic ductal adenocarcinoma	30.6	MALAT1 HOTTIP HOTAIR AFAP1-AS1
10	laryngeal squamous cell carcinoma	30.6	MALAT1 HOXA11-AS HOTAIR CCAT1
11	thyroid cancer, nonmedullary, 1	30.6	MEG3 MALAT1 LINC-ROR HOTTIP HOTAIR BANCR
12	kidney cancer	30.5	MEG3 MALAT1 HOTAIR GAS5
13	bladder cancer	30.5	MEG3 MALAT1 HOTAIR GAS5 FOXD2-AS1 EPIST
14	myeloma, multiple	30.5	MEG3 MALAT1 HOTAIR GAS5 CCAT1
15	retinitis pigmentosa 11	30.4	MIR296 HOTAIR GAS5 CYTOR CCAT1
16	liver cirrhosis	30.4	MEG3 MALAT1 HOTAIR GAS5
17	ovarian epithelial cancer	30.4	MEG3 MALAT1 HOTAIR CCAT1
18	squamous cell carcinoma, head and neck	30.4	LUCAT1 HOTAIR EPIST CYTOR
19	cervical cancer	30.4	MEG3 MALAT1 HOXA11-AS HOTAIR GAS5 CCAT1
20	vulva squamous cell carcinoma	30.4	MEG3 MALAT1
21	hepatocellular carcinoma	30.4	MIR296 MEG3 MALAT1 LINC-ROR HOXA11-AS HOTTIP
22	leukemia, acute myeloid	30.4	MIR296 MEG3 MALAT1 HOTAIR CCAT1
23	nasopharyngeal carcinoma	30.2	MIR296 MEG3 MALAT1 LINC00460 LINC-ROR HOTAIR
24	lung cancer susceptibility 3	30.2	MIR296 MEG3 MALAT1 LINC-ROR HOTAIR GAS5
25	renal cell carcinoma, nonpapillary	30.2	MIR296 MEG3 MALAT1 LUCAT1 LINC-ROR HOTAIR
26	gallbladder cancer	30.2	MEG3 MALAT1 LINC-ROR HOTAIR CYTOR CCAT1
27	pancreatic cancer	30.1	MEG3 MALAT1 LINC-ROR HOTTIP HOTAIR GAS5
28	osteogenic sarcoma	30.0	MEG3 MALAT1 LUCAT1 HOXA11-AS HOTTIP HOTAIR
29	gastric cancer	29.9	MEG3 MALAT1 LINC-ROR HOXA11-AS HOTTIP HOTAIR
30	glioma	29.9	MIR296 MEG3 MALAT1 LUCAT1 HOXA11-AS HOTTIP
31	ovarian cancer	29.9	MIR296 MEG3 MALAT1 LUCAT1 LINC-ROR HOXA11-AS
32	melanoma	29.9	MEG3 MALAT1 LINC-ROR HOTAIR GAS5 BANCR
33	lung cancer	29.7	MIR296 MEG3 MALAT1 LUCAT1 LINC00460 LINC-ROR
34	colorectal cancer	29.6	MIR296 MEG3 MALAT1 LINC00460 LINC-ROR HOXA11-AS
35	tylosis with esophageal cancer	11.3
36	basaloid squamous cell carcinoma	10.8
37	esophagitis	10.7
38	neutropenia	10.6
39	immunodeficiency, common variable, 10	10.6
40	achalasia	10.5
41	thoracic cancer	10.5
42	factor viii deficiency	10.5
43	head and neck cancer	10.5
44	pituitary tumors	10.5
45	factor vii deficiency	10.5
46	adenoid cystic carcinoma	10.5
47	ataxia-telangiectasia	10.5
48	xeroderma pigmentosum, variant type	10.5
49	telangiectasis	10.5
50	chromosome 18p deletion syndrome	10.4

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Human phenotypes related to Esophagus Squamous Cell Carcinoma:

⁵⁸ ³⁰ (show all 8)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	feeding difficulties in infancy ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008872
2	clinodactyly of the 5th toe ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001864
3	esophageal carcinoma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0011459
4	nausea and vomiting ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002017
5	abnormality of the voice ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001608
6	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012735
7	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100749
8	lymphadenopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002716

Sources

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Trioxsalen

Approved

Phase 3

3902-71-4

5585

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Nedaplatin

Approved, Investigational

Phase 3

95734-82-0

Durvalumab

Approved, Investigational

Phase 3

1428935-60-7

Tegafur

Approved, Investigational

Phase 3

17902-23-7

5386

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Nivolumab

Approved

Phase 3

946414-94-4

Ipilimumab

Approved

Phase 3

477202-00-9

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Fluorouracil

Approved

Phase 3

51-21-8

3385

Panitumumab

Approved, Investigational

Phase 3

339177-26-3

Dihematoporphyrin ether

Investigational

Phase 3

97067-70-4

Diethyl ether

Experimental

Phase 3

60-29-7

3283

3,4-Dihydroxycinnamic Acid

Experimental, Investigational

Phase 3

331-39-5, 501-16-6

689043

Andrographolide

Investigational

Phase 3

5508-58-7

343585

Photosensitizing Agents

Phase 3

Hematoporphyrins

Phase 3

Hematoporphyrin Derivative

Phase 3

Dermatologic Agents

Phase 3

Tea

Phase 3

Antioxidants

Phase 3

Megestrol

Phase 3

3562-63-8

3080587 19090

Antineoplastic Agents, Hormonal

Phase 3

Contraceptives, Oral, Hormonal

Phase 3

Contraceptives, Oral

Phase 3

Contraceptive Agents

Phase 3

topoisomerase I inhibitors

Phase 3

Analgesics

Phase 3

Antirheumatic Agents

Phase 3

Platelet Aggregation Inhibitors

Phase 3

Anti-Inflammatory Agents, Non-Steroidal

Phase 3

Analgesics, Non-Narcotic

Phase 3

Anti-Inflammatory Agents

Phase 3

Antiviral Agents

Phase 3

Antiprotozoal Agents

Phase 3

Antiparasitic Agents

Phase 3

Andrographis

Phase 3

Chirata

Phase 3

Vitamins

Phase 3

Trace Elements

Phase 3

Antidotes

Phase 3

Micronutrients

Phase 3

Protective Agents

Phase 3

Hormones

Phase 3

Calcium, Dietary

Phase 3

Interventional clinical trials:

(show top 50) (show all 425)

#	Name	Status	NCT ID	Phase	Drugs
1	Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Unknown status	NCT02628665	Phase 3	photosensitizer(photofrin)
2	Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer	Unknown status	NCT02025036	Phase 3	Capecitabine(Aibin);Oxaliplatin(Aiheng)
3	Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer	Unknown status	NCT02607540	Phase 3
4	Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy	Unknown status	NCT02603159	Phase 3	Capecitabine(Aibin)
5	A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma	Unknown status	NCT02570893	Phase 3	Paclitaxel and carboplatin
6	An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma	Unknown status	NCT02677597	Phase 3	Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
7	Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study	Unknown status	NCT02319187	Phase 3	S1;S-1;irinotecan
8	A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma	Unknown status	NCT02409186	Phase 3	Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
9	A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence	Unknown status	NCT01402180	Phase 2, Phase 3	chemotherapy
10	Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma	Unknown status	NCT02891083	Phase 3	Adjuvant chemotherapy (Paclitaxel and Cisplatin)
11	Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;	Unknown status	NCT01745107	Phase 3
12	Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial	Unknown status	NCT01398449	Phase 3
13	Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial.	Unknown status	NCT01496521	Phase 3	Aspirin
14	Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial	Unknown status	NCT02604615	Phase 3	Capecitabine(Aibin);Oxaliplatin(Aiheng)
15	An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas	Unknown status	NCT02611700	Phase 3	Nimotuzumab;Paclitaxel;Cisplatin;Placebo
16	GASC1 Inhibitor Caffeic Acid for Advanced Squamous Esophageal Cell Cancer (ESCC): a Multicenter, Phase II Trial (GiCAEC)	Unknown status	NCT04648917	Phase 3	Caffeic acid
17	Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer	Unknown status	NCT02375997	Phase 3
18	Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy	Completed	NCT02644408	Phase 3	Megestrol（Yining）
19	A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Completed	NCT02399306	Phase 3	Enteral nutrition
20	A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma	Completed	NCT02395705	Phase 3	cisplatin and paclitaxel
21	A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma	Completed	NCT01591135	Phase 3	Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
22	A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial	Completed	NCT02459457	Phase 3	Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
23	A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer	Completed	NCT01137123	Phase 3	adjuvant chemotherapy
24	The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer	Completed	NCT04196075	Phase 3	Andrographis Paniculata
25	A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)	Completed	NCT02564263	Phase 3	paclitaxel;docetaxel;irinotecan
26	A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)	Completed	NCT03933449	Phase 3	paclitaxel;docetaxel;irinotecan
27	S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study	Completed	NCT02813967	Phase 3	S-1
28	Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer	Recruiting	NCT03801876	Phase 3	Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
29	Neoadjuvant Immunotherapy Combined With Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (cII-III Stage): A Multi-center Prospective Randomized Clinical Trial	Recruiting	NCT04973306	Phase 2, Phase 3	Tislelizumab
30	Adjuvant Esophagectomy Versus Chemoradiation for Patients With Clinical Stage N0 and Pathological Stage T1b (After Endoscopic Submucosal Dissection, ESD) Esophageal Squamous Cell Carcinoma (Ad-ESD Trial): a Multicentric, Open Label, Randomized Trial	Recruiting	NCT04135664	Phase 3
31	A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)	Recruiting	NCT03748134	Phase 3	Placebo;Cisplatin;Paclitaxel;Fluorouracil
32	Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)	Recruiting	NCT04138212	Phase 3	Paclitaxel, Cisplatin
33	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)	Recruiting	NCT04550260	Phase 3	Durvalumab;Placebo;cisplatin + fluorouracil;cisplatin + capecitabine
34	A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma	Recruiting	NCT04280822	Phase 3	Neoadjuvant immunochemotherapy
35	A Randomized Phase Ⅱ/Ⅲ Trial of Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma	Recruiting	NCT03600831	Phase 2, Phase 3	Docetaxel plus cisplatin
36	NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial)	Recruiting	NCT04460352	Phase 3	Carboplatin, paclitaxel;Cisplatin, paclitaxel;Oxaliplatin, calcium folinate, 5-fluorouracil
37	Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial	Recruiting	NCT02461043	Phase 3	paclitaxel; cisplatin
38	Multicenter Prospective Randomized Controlled Study of Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone in the Treatment of pN1-2 (pT1b-3N1-2M0) Thoracic Esophageal Squamous Cell Carcinoma	Recruiting	NCT04009265	Phase 3
39	A Randomized Phase II/III Study of Paclitaxel/Cisplatin Versus Cisplatin/5-fluorouracil in Neoadjuvant Chemoradiation Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)	Recruiting	NCT03623737	Phase 2, Phase 3	neoadjuvant chemoradiation
40	A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002)	Recruiting	NCT04807673	Phase 3	Paclitaxel;Cisplatin
41	A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Recruiting	NCT04848753	Phase 3
42	Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study	Recruiting	NCT04415853	Phase 3	Lerotinib;Irinotecan/Tegafur
43	A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma	Recruiting	NCT02465736	Phase 3	Docetaxel;Cisplatin;Vinorelbine
44	A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma	Recruiting	NCT05213312	Phase 2, Phase 3	Nivolumab;Cisplatin;Paclitaxel;5Fluorouracil
45	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy	Recruiting	NCT04543617	Phase 3	Tiragolumab;Atezolizumab;Tiragolumab Matching Placebo;Atezolizumab Matching Placebo
46	Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma	Recruiting	NCT05357846	Phase 3	Sintilimab;Paclitaxel;Cisplatin
47	A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)	Recruiting	NCT04210115	Phase 3	placebo;cisplatin;5-FU;leucovorin;levoleucovorin;oxaliplatin
48	A Phase III Study of Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma	Recruiting	NCT03790553	Phase 3
49	A Randomized Controlled Phase III Trial of Comparing Local Field With Additional Prophylactic Irradiation in Chemoradiotherapy for Clinical-T1bN0M0 Esophageal Cancer	Recruiting	NCT04328948	Phase 3
50	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma	Recruiting	NCT04949256	Phase 3	Pembrolizumab;Lenvatinib;Cisplatin;5-FU;Oxaliplatin;Leucovorin;Levoleucovorin;Paclitaxel

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Sources

Genetic Tests for Esophagus Squamous Cell Carcinoma

Sources

Anatomical Context for Esophagus Squamous Cell Carcinoma

Organs/tissues related to Esophagus Squamous Cell Carcinoma:

FMA: Esophagus

MalaCards : Lymph Node, Testis, T Cells, Lung, Endothelial, Breast, Spinal Cord

Sources

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show top 50) (show all 13019)

#	Title	Authors	PMID	Year
1	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
2	The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. ⁶² ⁴⁶	Hong L...Fan D	20485139	2010
3	Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. ⁵³ ⁶²	Jain M...Mittal B	17912028	2007
4	Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. ⁵³ ⁶²	Lu XM...Wen H	15968714	2005
5	[Flow cytometric detection and significance of four cyclins in esophageal cancer]. ⁵³ ⁶²	Du Y...Zuo LF	15634523	2004
6	The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. ⁵³ ⁶²	Nakajima Y...Kawano T	15132777	2004
7	Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. ⁵³ ⁶²	Wang N...Wu M	12439907	2002
8	Endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in patients with cirrhosis and esophageal varices. ⁶²	Mochimaru T...Ohira H	35898831	2023
9	Mechanisms of function and clinical potential of exosomes in esophageal squamous cell carcinoma. ⁶²	Zhao L...Yang A	36328162	2023
10	Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. ⁶²	Wu X...Pang Q	36425536	2023
11	Controlling Nutritional Status Score Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma: Optimal Timing of Evaluation of Patients Undergoing Neoadjuvant Treatment. ⁶²	Nonogaki I...Kodera Y	36197488	2023
12	Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma. ⁶²	Yuan J...Fu J	36279981	2023
13	Evaluation of Immunoexpression of AJUBA Protein in Normal Oral Mucosa and Oral Squamous Cell Carcinoma. ⁶²	Desai P...Mane DR	36222508	2023
14	Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis. ⁶²	Zhang L...Jia L	36265256	2023
15	N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. ⁶²	Wang X...Liu R	36169023	2023
16	Azelnidipine may be a valuable drug for chemoprevention of ESCC with high MEK1/2 levels. ⁶²	Qian H	36420305	2022
17	Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma. ⁶²	Ko JM...Lung ML	36261585	2022
18	Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma. ⁶²	Luo Y...Xu YW	35930383	2022
19	Radiation Induced Liver Injury: Collateral Damage Radiologically Simulating Interval Metastasis in Carcinoma Esophagus; a Diagnostic Dilemma Resolved Through Liver Biopsy. ⁶²	Bakshi N...Duggal R	35470748	2022
20	Evaluation of Expression Of ADAM 10 as a Predictor of Lymph Node Metastasis in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. ⁶²	Jain R...Salunke M	35771404	2022
21	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. ⁶²	Zhou N...Weston BR	34883083	2022
22	Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases. ⁶²	Liu L...Guo YL	36473140	2022
23	Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. ⁶²	Liang M...Zhou F	35435776	2022
24	Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma. ⁶²	Wang X...Zhou F	34935568	2022
25	Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients. ⁶²	Liu Z...Zhang H	34253568	2022
26	Molecular characteristics of multifocal esophageal squamous cell carcinomas to discriminate multicentric origin from intramural metastasis. ⁶²	Li W...Xue L	36098222	2022
27	Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT? ⁶²	Wei X...Li Y	36226869	2022
28	Using texture and colour enhancement imaging to evaluate gastrointestinal diseases in clinical practice: a review. ⁶²	Sugimoto M...Kawai T	36420822	2022
29	ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma. ⁶²	Song Y...Wei X	36470544	2022
30	Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study. ⁶²	Cui Y...Li B	36473995	2022
31	Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models. ⁶²	Xie C...Yang H	36018524	2022
32	ASO Visual Abstract: Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine CT Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models. ⁶²	Xie C...Yang H	36068426	2022
33	ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma. ⁶²	Shimizu H...Otsuji E	35986132	2022
34	ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma. ⁶²	Xie C...Yang H	35933539	2022
35	ASO Visual Abstract: NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma. ⁶²	Shimizu H...Otsuji E	36002704	2022
36	Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. ⁶²	Hamai Y...Okada M	36456150	2022
37	Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. ⁶²	Shi Z...Chen Y	36454568	2022
38	A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma. ⁶²	Ma C...Luo H	36265781	2022
39	High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma. ⁶²	Li H...Wen Z	36272333	2022
40	A matched cohort comparison of endoscopic resection, chemoradiation and esophagectomy in the treatment of early-stage esophageal squamous cell carcinoma. ⁶²	Swanson J...Baker MS	36473738	2022
41	Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. ⁶²	Chen Y...He C	36473119	2022
42	Genetic variant in miR-17-92 cluster binding sites is associated with esophageal squamous cell carcinoma risk in Chinese population. ⁶²	Shen Y...Liu F	36461008	2022
43	The prognostic value of positron emission tomography/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy. ⁶²	Zhang W...Wang Q	36345769	2022
44	CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. ⁶²	Tian T...Deng W	36427397	2022
45	Esophageal squamous cell carcinoma darkly stained with iodine. ⁶²	Tanaka I...Kawachi H	36458865	2022
46	NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma. ⁶²	Shimizu H...Otsuji E	35972670	2022
47	Traction-assisted circumferential endoscopic submucosal dissection of early esophageal squamous cell carcinoma, followed by metal stent insertion and fixation with a dedicated clip. ⁶²	Aslam SP...Bhandari P	35180786	2022
48	Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data". ⁶²	Sichao W...Guibin Q	35129491	2022
49	MicroRNAs in esophageal squamous cell carcinoma: Application in prognosis, diagnosis, and drug delivery. ⁶²	Mohammadi E...Memar MY	36356334	2022
50	TWIST1 activates cancer stem cell marker genes to promote epithelial-mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma. ⁶²	Khales SA...Abbaszadegan MR	36474162	2022

Sources

Genes for Esophagus Squamous Cell Carcinoma

Genes related to Esophagus Squamous Cell Carcinoma (5 elite genes):

(show all 46)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR296	MicroRNA 296	RNA Gene	350	Causal ⁴⁶	20485139
2	DLEC1	DLEC1 Cilia And Flagella Associated Protein	Protein Coding	25	Candidate gene tested ⁵⁸	10213508
3	RNF6	Ring Finger Protein 6	Protein Coding	25	Candidate gene tested ⁵⁸	12154016
4	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	25	Candidate gene tested ⁵⁸	17680270
5	WWOX	WW Domain Containing Oxidoreductase	Protein Coding	25	Susceptibility factor ⁵⁸	11956080 22213016
6	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	150	Experimental evidence: Expression ³⁷	26756568 27577754
7	BANCR	BRAF-Activated Non-Protein Coding RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	27470379
8	CASC9	Cancer Susceptibility 9	RNA Gene	150	Experimental evidence: Regulation ³⁷	29424900 29511340
9	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	27956498
10	CFLAR-AS1	CFLAR Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	27855375
11	CYTOR	Cytoskeleton Regulator RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	27855375
12	EPIST	Esophagus Epithelial Intergenic Associated Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	29524086
13	FOXD2-AS1	FOXD2 Adjacent Opposite Strand RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	29286915
14	GAS5	Growth Arrest Specific 5	RNA Gene	150	Experimental evidence: Regulation ³⁷	29170131
15	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Expression ³⁷	24022190 27810266 27816685 (more) 28376832 29156804
16	HOTTIP	HOXA Distal Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	27806322 28534516
17	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	29575836
18	LINC00460	Long Intergenic Non-Protein Coding RNA 460	RNA Gene	150	Experimental evidence: Expression ³⁷	28939763 29409459
19	LINC01233	Long Intergenic Non-Protein Coding RNA 1233	RNA Gene	150	Experimental evidence: Expression ³⁷	24522499
20	LINC02231	Long Intergenic Non-Protein Coding RNA 2231	RNA Gene	150	Experimental evidence: Interaction ³⁷	28157654
21	LINC-ROR	Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming	RNA Gene	150	Experimental evidence: Regulation ³⁷	27872710
22	LUCAT1	Lung Cancer Associated Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	29247823
23	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Interaction ³⁷	27935117 28150831
24	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Expression ³⁷	27778235 28405686 28539329
25	NKILA	NF-KappaB Interacting LncRNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	29379981
26	NORAD	Non-Coding RNA Activated By DNA Damage	RNA Gene	150	Experimental evidence: Regulation ³⁷	28482344
27	NPTN-IT1	NPTN Intronic Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	26935396
28	PHB1P1	PHB1 Pseudogene 1	Pseudogene	150	Experimental evidence: Interaction ³⁷	28404970
29	POU3F3	POU Class 3 Homeobox 3	Protein Coding	150	Experimental evidence: Regulation ³⁷	27855375
30	PVT1	Pvt1 Oncogene	RNA Gene	150	Experimental evidence: Interaction ³⁷	28404954
31	SBF2-AS1	SBF2 Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	29552140
32	SNHG1	Small Nucleolar RNA Host Gene 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	29081407
33	SNHG16	Small Nucleolar RNA Host Gene 16	RNA Gene	150	Experimental evidence: Regulation ³⁷	29416674
34	TDRG1	Testis Development Related 1	RNA Gene	150	Experimental evidence: Expression ³⁷	27583835
35	TERLR1	TERT Regulating LncRNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	27726103
36	TINCR	TINCR Ubiquitin Domain Containing	Protein Coding	150	Experimental evidence: Regulation ³⁷	26833746
37	TP73-AS1	TP73 Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	26799587
38	TTN-AS1	TTN Antisense RNA 1	RNA Gene	150	Experimental evidence: Expression ³⁷	29101304
39	TUG1	Taurine Up-Regulated 1	Protein Coding	150	Experimental evidence: Locus ³⁷	27339553
40	XIST	X Inactive Specific Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	29100288
41	EGFR	Epidermal Growth Factor Receptor	Protein Coding	29.12	Likely pathogenic ⁵ DISEASES inferred ¹⁴	25157968
42	CTNNB1	Catenin Beta 1	Protein Coding	29.04	Likely pathogenic ⁵ DISEASES inferred ¹⁴	25157968
43	KLF4	KLF Transcription Factor 4	Protein Coding	12.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12439907 12518228 19361279
44	CCND1	Cyclin D1	Protein Coding	10.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17912028 12899785 15634523
45	CDK4	Cyclin Dependent Kinase 4	Protein Coding	8.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15634523
46	CBX8	Chromobox 8	Protein Coding	8.32	GeneCards inferred via : Summaries (show sections)

Sources

Variations for Esophagus Squamous Cell Carcinoma

ClinVar genetic disease variations for Esophagus Squamous Cell Carcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	EGFR	NM_005228.5(EGFR):c.2198C>T (p.Pro733Leu)	SNV	Likely Pathogenic	376076	rs121913446	GRCh37: 7:55242428-55242428 GRCh38: 7:55174735-55174735
2	CTNNB1	NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn)	SNV	Likely Pathogenic	376228	rs28931588	GRCh37: 3:41266097-41266097 GRCh38: 3:41224606-41224606

Cosmic variations for Esophagus Squamous Cell Carcinoma:

⁸ (show top 50) (show all 11188)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM142081527	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1006+2T>A	p.?	19:58086172-58086172	18
2	COSM140961271	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.838+2T>A	p.?	19:58086172-58086172	18
3	COSM109468109	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.433+2T>A	p.?	19:58086172-58086172	18
4	COSM86897778	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.838+2T>A	p.?	19:58086172-58086172	18
5	COSM98059731	ZNF831	oesophagus,NS,carcinoma,squamous cell carcinoma	c.605T>C	p.L202P	20:59191624-59191624	18
6	COSM149923539	ZNF831	oesophagus,NS,carcinoma,squamous cell carcinoma	c.605T>C	p.L202P	20:59191624-59191624	18
7	COSM88515958	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.938C>G	p.S313C	17:82831517-82831517	18
8	COSM88515712	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.668C>G	p.S223*	17:82831787-82831787	18
9	COSM138690836	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-31C>G	p.?	17:82831517-82831517	18
10	COSM88513307	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.170C>G	p.S57*	17:82832285-82832285	18
11	COSM88514972	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.80G>C	p.C27S	17:82832375-82832375	18
12	COSM138689938	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-889G>C	p.?	17:82832375-82832375	18
13	COSM138689466	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-201C>G	p.?	17:82831687-82831687	18
14	COSM138688764	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-799C>G	p.?	17:82832285-82832285	18
15	COSM88514017	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.777C>A	p.Y259*	17:82831678-82831678	18
16	COSM88515841	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.37C>A	p.H13N	17:82832418-82832418	18
17	COSM138689254	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-192C>A	p.?	17:82831678-82831678	18
18	COSM88514274	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.768C>G	p.Y256*	17:82831687-82831687	18
19	COSM138690667	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-301C>G	p.?	17:82831787-82831787	18
20	COSM138690762	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-932C>A	p.?	17:82832418-82832418	18
21	COSM90465117	ZNF548	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1016A>C	p.H339P	19:57399267-57399267	18
22	COSM93683971	ZNF548	oesophagus,NS,carcinoma,squamous cell carcinoma	c.980A>C	p.H327P	19:57399267-57399267	18
23	COSM102366084	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	18
24	COSM102372996	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	18
25	COSM104733716	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	18
26	COSM109217250	ZNF230	oesophagus,NS,carcinoma,squamous cell carcinoma	c.87G>C	p.Q29H	19:44008861-44008861	18
27	COSM139548867	ZNF230	oesophagus,NS,carcinoma,squamous cell carcinoma	c.87G>C	p.Q29H	19:44008861-44008861	18
28	COSM100770466	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1117C>T	p.R373W	17:32369340-32369340	18
29	COSM100755139	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1210C>T	p.R404W	17:32369340-32369340	18
30	COSM90696431	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1219C>T	p.R407W	17:32369340-32369340	18
31	COSM139216379	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1210C>T	p.R404W	17:32369340-32369340	18
32	COSM91133838	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1162C>T	p.R388W	17:32369340-32369340	18
33	COSM131330822	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
34	COSM94832002	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
35	COSM88860826	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
36	COSM88887411	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.86A>T	p.E29V	23:152919042-152919042	18
37	COSM89189081	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.71A>T	p.E24V	23:152919042-152919042	18
38	COSM94818098	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
39	COSM129903764	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
40	COSM112129853	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	18
41	COSM125164549	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.9439C>T	p.P3147S	8:76863231-76863231	18
42	COSM125167660	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6188C>A	p.P2063H	8:76853187-76853187	18
43	COSM127363671	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.2120C>G	p.S707C	8:76706208-76706208	18
44	COSM127389059	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.10574C>T	p.S3525F	8:76864288-76864288	18
45	COSM127376736	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.4099G>A	p.D1367N	8:76851020-76851020	18
46	COSM127405081	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.439G>T	p.E147*	8:76704527-76704527	18
47	COSM125134824	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6767G>A	p.R2256Q	8:76853766-76853766	18
48	COSM127390973	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.9517C>T	p.P3173S	8:76863231-76863231	18
49	COSM127363056	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6845G>A	p.R2282Q	8:76853766-76853766	18
50	COSM125162303	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.10496C>T	p.S3499F	8:76864288-76864288	18